AstraZeneca PLC (AZN) Institutional Investor Snapshot (1477 Funds, Q2 2026)

AZN ranks #245 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AZN is a top-conviction position for Investor AB — at 67.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Osaic Holdings, Inc. has added to its AZN position for two straight quarters, increasing it by $22.6M to reach $22.6M today.

Optiver Holding B.V. has trimmed its AZN position for two straight quarters, cutting it by $66.7M while still holding $17.1M.

AZN is down 0.5% today, but institutions show net buying of $12.1B this quarter — a divergence between today's price move and the underlying institutional flow.

AZN posted net income of $6.6B over the trailing twelve months.

• Profitable — net income of $6.6B over the trailing twelve months
• Revenue grew 14.4% year over year
• Net income improved year over year, from $4.7B to $6.6B
• Generated $14.6B in positive operating cash flow
• Current ratio of 0.94x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.34x equity — within a conventional range